Human Delon Hannes's Form 4/A amendment
AmendedCryomass Technologies, Inc. (CRYM) · filed Nov 18, 2021
- Accession no.
- 0001213900-21-060526
- Filed
- Nov 18, 2021, 3:44 PM ET
- Trade date
- Nov 15, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Nov 15, 2021
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $152.0K. It was filed 3 days after the trade.
This amendment replaces 0001213900-21-059687 (filed Nov 15, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Human Delon HannesCIK 0001809272 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2021 | Common Stock | PPurchaseAcquired | +760,000 | $0.20 | +$152,000 | 760,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2021 | Common Stock | PPurchaseAcquired | +760,000 | –F2 | – | 2,260,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Health Diplomats Pte Ltd is a Singapore exempt private company limited by shares 100% owned by Mr. Human.
- F2
The purchase reflects a Unit purchase, each Unit consisting of (a) 10,000 shares of common stock at a price of $0.20 per share and (b) one common stock purchase warrant exercisable to purchase 10,000 additional shares of common stock of the corporation (each such additional share a "Warrant Share") at an exercise price of $0.40 per Warrant Share. For the purposes of this report no purchase price has been attributed to the warrant.
Referenced by the price of 1 transaction in Table II.